Tag Archives: RA

Business, Finance, Occupation & Industry

Genesee & Wyoming Reports Traffic for March 2013 and the First Quarter of 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Genesee & Wyoming Reports Traffic for March 2013 and the First Quarter of 2013

GREENWICH, Conn.–(BUSINESS WIRE)– Genesee & Wyoming Inc. (G&W) (NYS: GWR) today reported traffic volumes for March 2013 and the first quarter of 2013.

Beginning in January 2013, G&W is reporting consolidated traffic volumes including carloads from RailAmerica Inc. (RA) railroads that were previously reported separately. To provide comparative context for 2013 consolidated traffic volumes, G&W is providing supplemental 2012 carload information on a pro forma basis as though the RA railroads were owned by G&W on January 1, 2012. In addition, G&W has amended RA‘s 2012 carload information to conform with G&W’s reporting methodology.

G&W’s traffic in March 2013 was 154,077 carloads, an increase of 77,031 carloads, or 100.0%, compared to G&W’s traffic in March 2012, and an increase of 5,198 carloads, or 3.5%, compared to total March 2012 carloads pro forma for the RA acquisition. G&W’s traffic in the first quarter of 2013 was 450,304 carloads, an increase of 228,126 carloads, or 102.7%, compared to G&W’s traffic in the first quarter of 2012, and an increase of 19,387 carloads, or 4.5%, compared to total first quarter of 2012 pro forma for the RA acquisition.

The tables below set forth consolidated summary carload information for March 2013 and March 2012:

           

From: http://www.dailyfinance.com/2013/04/11/genesee-wyoming-reports-traffic-for-march-2013-and/
Business, Finance, Occupation & Industry

Why Rigel Is Poised to Bounce Back

Leave a comment

By Brian Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, clinical-stage drug development company Rigel Pharmaceuticals has earned a respected four-star ranking.

With that in mind, let’s take a closer look at Rigel and see what CAPS investors are saying about the stock right now.

Rigel facts

Headquarters (founded)

South San Francisco, Calif. (1996)

Market Cap

$392.1 million

Industry

Biotechnology

Trailing-12-Month Revenue

$2.3 million

Management

Chairman/CEO James Gower
President/COO Raul Rodriguez

Return on Equity (average, past 3 years)

(17.6%)

Cash/Debt

$298.2 million / $0

Competitors

Amgen

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 891 members who have rated Rigel believe the stock will outperform the S&P 500 going forward.

Just this past Friday, one of those Fools, All-Star zzlangerhans, tapped Rigel as a particularly attractive bargain opportunity:

The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib … as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.

As of the end of 2012, Rigel has about [$300M] in liquid assets to support a market cap of [$392M] at [Friday’s] close. That’s a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash.

If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its strong four-star rating, Rigel may not be your top choice.

We’ve found another growth play we are incredibly excited about — excited enough to dub it “The Only Stock You Need to Profit from the NEW Technology Revolution.” We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won’t be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Rigel Is Poised to Bounce Back originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Growing Aches and Pains Sink Rigel Pharmaceuticals

Leave a comment

By Sean Williams, The Motley Fool

Filed under:

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Rigel Pharmaceuticals imploded today, losing as much as 37% of its value after licensing partner AstraZeneca announced that the first phase 3 study of Fostamatinib failed to meet one of the two designed primary endpoints of the trial.

So what: Fostamatinib — a treatment for rheumatoid arthritis, or RA, which is a progressive disease that causes inflammation of the joints and surrounding tissues – achieved a statistically significant improvement in the ACR20 response rate in terms of symptoms for both dosage subsets at 24 weeks. However, it didn’t show any improvement with regard to progression of joint damage according to x-ray tests. Further, Fostamatinib was generally well-tolerated in trials, but it once again did lead to hypertension, which is a concern not taken lightly by the Food and Drug Administration.

Now what: That’s now two strikes for Rigel Pharmaceuticals with Fostamatinib — one more and it and the drug can take a seat on the bench as far as I’m concerned. In December, Fostamatinib proved to be an inferior treatment option for patients with RA in a direct comparison to AbbVie‘s blockbuster drug Humira — strike one. Today, it failed to demonstrate any statistically significant improvement in suppressing joint damage — strike two. Tack on the fact that Pfizer‘s Xeljanz, another FDA-approved treatment for RA, scored higher than Fostamatinib in its ACR20 response rate in its phase 3 tests and doesn’t have hypertension concerns, and you can see that even if Fostamatinib somehow gains approval, its uses appear to be extremely limited. Rigel still has two additional late-stage trials ongoing with Fostamatinib, but the expectation that they will be a success are quickly waning.

Craving more input? Start by adding Rigel Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

Is there hope beyond Humira for AbbVie?
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company’s golden goose, Humira, is cooked. The Fool’s brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

var FoolAnalyticsData = FoolAnalyticsData || []; …read more

Source: FULL ARTICLE at DailyFinance

Linux

Delete lines in a file

Leave a comment

By sonia102

Hi

This is a sample of my data file.

##field PH01000000 1 4869017
#PH01000000G0240
WWW278545G0240 P.he_model_v1.0 erine 119238 121805 . – . ID=PH01000000G0240;Description=”zinc finger, C3HC4 type domain containing protein, expressed”
WWW278545G0240 P.he_model_v1.0 RA 119238 121805 . – . ID=PH01000000G0240.mRNA;Parent=PH01000000G0240
WWW278545G0240 P.he_model_v1.0 NGS 120721 121773 . – . ID=PH01000000G0240.CDS;Parent=PH01000000G0240

#PH01000000G0250
WWW278545G0250 P.he_model_v1.0 erine 125260 126544 . – . ID=PH01000000G0250;Description=”FERONIA receptor-like kinase, putative, expressed”
WWW278545G0250 P.he_model_v1.0 RA 125260 126544 . – . ID=PH01000000G0250.mRNA;Parent=PH01000000G0250
WWW278545G0250 P.he_model_v1.0 NGS 125971 126544 . – . ID=PH01000000G0250.CDS;Parent=PH01000000G0250

#PH01000000G0290
WWW278545G0290 P.he_model_v1.0 erine 151334 153926 . + . ID=PH01000000G0290;Description=”DUF581 domain containing protein, expressed”
WWW278545G0290 P.he_model_v1.0 RA 151334 153926 . + . ID=PH01000000G0290.mRNA;Parent=PH01000000G0290

I want to use some basic vi command or any comand to delete all those lines whose third column entry is RA or NGS.

I want to retain only those lines whos 3rd column is erine.

Is this possible?

Thanks

…read more
Source: FULL ARTICLE at The UNIX and Linux Forums

Business, Finance, Occupation & Industry

XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthrit

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

XELJANZ ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYS: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ® (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. XELJANZ may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate. The recommended dose of XELJANZ is 5 mg twice daily.

XELJANZ will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited. Pfizer and Takeda also currently co-promote the RA drug Enbrel® (etanercept) in Japan.

XELJANZ (ZEL’ JANZ’) is the first approved oral treatment in a new class of medicines known as Janus kinase (JAK) inhibitors. Initially, XELJANZ will be made available in Japan to medical institutions participating in an all-patient surveillance program.

“RA is a serious and disabling disease and there is a need for new treatment options, as a significant number of patients do not adequately respond to current therapies,” said Mark Swindell, Head of Pfizer Specialty Care Business Unit in Japan. “We are proud of our strong portfolio of treatments for inflammatory disorders in Japan, and we are pleased with the approval of XELJANZ, which allows us to offer an additional treatment option for RA patients.”

Unlike biologic therapies that target RA outside the cell, XELJANZ targets the disease from inside the cell. It is specifically designed to inhibit the Janus kinase (JAK) pathways, which are signalling pathways inside the cell that play a role in the inflammation involved in RA.

The approval of XELJANZ in Japan is supported by a multi-study, global clinical development program, which evaluated XELJANZ in approximately 5,000 patients across various RA patient populations. The application also included data from Japanese subjects from two phase 2 studies, one phase 3 study and an ongoing long-term extension study. Across five global pivotal trials, XELJANZ 5 mg twice daily demonstrated efficacy, whether administered alone or in combination with a non-biologic DMARD, such as methotrexate, in patients who had a previous inadequate response to non-biologic or biologic DMARDs, including tumor necrosis factor (TNF) inhibitors.

XELJANZ is approved for the treatment of RA patients who have had an inadequate response to existing therapies. Notable safety findings observed in the XELJANZ …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Antares Pharma Reports Fourth Quarter and Full Year 2012 Operating and Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Antares Pharma Reports Fourth Quarter and Full Year 2012 Operating and Financial Results

Significant Pipeline Progress Achieved – OTREXUP™ On Track For Commercial Launch

EWING, N.J.–(BUSINESS WIRE)– Antares Pharma, Inc. (NAS: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2012.

Recent Highlights

  • Announced the submission and acceptance of OTREXUP™ New Drug Application (NDA) by the Food and Drug Administration (FDA). OTREXUP™ is a potential new product under development for subcutaneous self-administration of methotrexate (MTX) to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.
  • Announced positive results from OTREXUP™ clinical study which was designed to compare the relative systemic availability of MTX. Following administration of OTREXUP™, the systemic availability of MTX increased proportionately at every dose level studied thereby extending the range of exposure significantly compared to patients receiving oral therapy at doses of 15mg to 25mg.
  • Conducted a Pre-Investigational New Drug (Pre-IND) meeting with the FDA to discuss a clinical development program for VIBEX™ QS T (testosterone replacement therapy). Clinical development path forward has been identified and the development plan is designed to target a launch date in 2016.
  • Increased total revenue to $5.5 million and $22.6 million for the three months and year ended December 31, 2012, respectively, from $5.4 million and $16.5 million, respectively, in the comparable periods of the prior year.
  • Completed a public offering of the Company’s common stock at a purchase price of $4.00 per share with net proceeds of approximately $53.3 million which included the underwriters exercised overallotment option.
  • OTREXUP™ NDA filed early, Prescription Drug User Fee Act (PDUFA) fee recorded in fourth quarter operating results.
  • Entered into a new commercial agreement with Teva under which we will manufacture and supply a packaged sumatriptan auto injector for the treatment of migraine. Received an upfront cash payment, a potential milestone payment on commercial launch and a 50/50 split of potential net profits.
  • Ended the year with $85.2 million in cash and investments and …read more
    Source: FULL ARTICLE at DailyFinance
Business, Finance, Occupation & Industry

Genesee & Wyoming Reports Traffic for February 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Genesee & Wyoming Reports Traffic for February 2013

GREENWICH, Conn.–(BUSINESS WIRE)– Genesee & Wyoming Inc. (G&W) (NYS: GWR) today reported traffic volumes for February 2013.

Beginning in January 2013, G&W is reporting consolidated traffic volumes including carloads from RailAmerica Inc. (RA) railroads that were previously reported separately. To provide comparative context for 2013 consolidated traffic volumes, G&W is providing supplemental 2012 carload information on a pro forma basis as though the RA railroads were owned by G&W on January 1, 2012. In addition, G&W has amended RA‘s 2012 carload information to conform with G&W’s reporting methodology.

G&W’s traffic in February 2013 was 140,200 carloads, an increase of 67,955 carloads, or 94.1%, compared to G&W’s traffic in February 2012, and an increase of 747 carloads, or 0.5%, compared to total February 2012 carloads pro forma for the RA acquisition. G&W’s traffic in the first quarter of 2013 through February was 296,227 carloads, an increase of 151,095 carloads, or 104.1%, compared to G&W’s traffic in the first quarter of 2012 through February, and an increase of 14,189 carloads, or 5.0%, compared to total first quarter of 2012 through February carloads pro forma for the RA acquisition.

The tables below set forth consolidated summary carload information for February 2013 and February 2012:

     


February 2012

…read more
Source: FULL ARTICLE at DailyFinance
Health

Is AbbVie's Overdependence on Humira a Long-Term Problem?

Leave a comment

By John LaMattina Recently, Abbott Laboratories broke itself up into two parts: Abbott, a diversified medical products company and AbbVie, a research based pharmaceutical company. The jewel of the new pharma company is Humira, an antibody that blocks a mediator known as TNF-alpha and is an important treatment for rheumatoid arthritis (RA) as well as other immunological disorders. It is also now the world?s top selling drug with 2012 sales estimated to be in excess of $9 billion.
Source: FULL ARTICLE at Forbes Health